ReviewJournal of neurodevelopmental disorders2019
White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies.
Review in Journal of neurodevelopmental disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Toward preventive interventions in developmental coordination disorder: in need of early behavioral markers?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- A Multi-parametric MRI and Machine Learning Study of Cerebellar Structure in Youth with Neurofibromatosis Type 1.Cerebellum (London, England) · 2026Article
- Article
- White matter microstructure of language pathways in non-verbal autism: insights from diffusion tensor imaging and myelin water imaging.Frontiers in human neuroscience · 2025Article
- Enhancing daily life for children with cognitive developmental delay through insights into brain development.Pediatric research · 2024Review
- White matter microstructure and functional connectivity in the brains of infants with Turner syndrome.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- White matter development and language abilities during infancy in autism spectrum disorder.Molecular psychiatry · 2024Article
- Beyond Diagnosis: Preliminary Study of Impact on Children and Parents in Neurodevelopmental Disorders and Juvenile Idiopathic Arthritis-Associated Uveitis.Diagnostics (Basel, Switzerland) · 2024Article
- EEG Correlates of Cognitive Functions in a Child with ASD and White Matter Signal Abnormalities: A Case Report with Two-and-a-Half-Year Follow-Up.Diagnostics (Basel, Switzerland) · 2023Article
- Autism spectrum disorder-specific changes in white matter connectome edge density based on functionally defined nodes.Frontiers in neuroscience · 2023Article
- Comparison of Serum VEGF, IGF-1, and HIF-1α Levels in Children with Autism Spectrum Disorder and Healthy Controls.Journal of autism and developmental disorders · 2021Article
- Emergence of Developmental Delay in Infants and Toddlers With anPediatrics · 2021Article
- Brain-Specific Oxysterols and Risk of Schizophrenia in Clinical High-Risk Subjects and Patients With Schizophrenia.Frontiers in psychiatry · 2021Article
- Role of Oligodendrocytes and Myelin in the Pathophysiology of Autism Spectrum Disorder.Brain sciences · 2020Review
- Poly(I:C) Challenge Alters Brain Expression of Oligodendroglia-Related Genes of Adult Progeny in a Mouse Model of Maternal Immune Activation.Frontiers in molecular neuroscience · 2020Article
- White matter and neurodevelopmental disorders: honoring Jean De Vellis through the work of the NICHD-funded intellectual and developmental disabilities research centers.Journal of neurodevelopmental disorders · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEarly intervention is a valuable tool to support the development of toddlers with neurodevelopmental disorders. With recent research advances in early identification that allow for pre-symptomatic detection of autism in infancy, scientists are looking forward to intervention during infancy. These advances may be supported by the identification of biologically based treatment and outcome measures that are sensitive and dimensional. The purpose of this review is to evaluate white matter neurodevelopment as a monitoring biomarker for early treatment of neurodevelopmental disorders. Fragile X syndrome (FXS) and autism spectrum disorder (ASD) as used as exemplars. White matter has unique neurobiology, including a prolonged period of dynamic development. This developmental pattern may make white matter especially responsive to treatment. White matter develops aberrantly in children with ASD and FXS. Histologic studies in rodents have provided targets for FXS pharmacological intervention. However, pharmaceutical clinical trials in humans failed to garner positive clinical results. In this article, we argue that the use of neurobiological monitoring biomarkers may overcome some of these limitations, as they are objective, not susceptible to placebo effects, and are dimensional in nature. SHORT
conclusionAs the field moves towards earlier detection and early intervention for neurodevelopmental disorders, we encourage scientists to consider the advantages of using neurobiological features as monitoring biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.